ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
Rhea-AI Summary
ProQR (Nasdaq: PRQR) announced management will present at the Citizens Life Sciences Conference on March 11, 2026 at 3:25pm ET. A live webcast and recording will be available via the company’s Investors & Media website events page. Archived webcasts will remain available for about 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – PRQR
In the Mar 4 session, PRQR gained 13.33%, reflecting a significant positive market reaction. Argus tracked a peak move of +6.3% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Board changes | Neutral | -2.0% | Planned rotation of two directors and search for new board members. |
| Jan 08 | Clinical and outlook | Positive | -2.8% | Encouraging AX-0810 Phase 1 safety/PK data and 2026 development outlook. |
| Dec 01 | Conference participation | Neutral | -9.4% | Participation in Evercore healthcare conference and related investor outreach. |
| Nov 06 | Quarterly results | Neutral | -7.1% | Q3 2025 financials with cash runway to mid-2027 and widened net loss. |
| Oct 20 | CTA authorization | Positive | +9.7% | CTA authorization for AX-0810 Phase 1 study and investor event announcement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including clinical and governance updates, often saw negative price reactions, with only one of the last five events aligning positively with its news tone.
Over the past several months, ProQR has highlighted governance changes, clinical progress, and investor outreach. A January 2026 update reported encouraging Phase 1 AX-0810 data, new development candidates, and $4.5M in 2025 milestones. Earlier, the company secured CTA authorization for AX-0810 and hosted investor events. Despite these developments, several announcements, including conference participation and Q3 2025 results, were followed by negative one-day price moves, showing a cautious market response to updates.
Key Terms
rna medical
adar-mediated medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET.
A live webcast and recording of this presentation will be available from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days following the presentation date.
About Axiomer™
ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
ProQR Therapeutics N.V.
Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
